The prognosis of refractory/relapsed acute myeloid leukemia (AML) remains poor. The
complete response (CR) rate after relapse is around 25%, with 11% of patients still alive …

Optimization of the salvage regimen is required to improve prognosis in primary refractory or
relapsed acute myeloid leukemia (AML). In fit patients, a bridge to allogeneic transplant is …

The objective of this work was to determine the safety and efficacy of gemtuzumab
ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the …

Gemtuzumab ozogamicin was recently approved in the United States for the treatment of
older patients with CD33-positive acute myeloid leukemia (AML) in first relapse. However …

We retrospectively evaluated the clinical efficacy and toxicity of gemtuzumab ozogamicin
(GO) in patients with relapsed acute myeloid leukemia (AML). Nineteen patients (median 70 …

CD33 is a suitable target to guide delivery of a toxic moiety to most acute myeloid leukemia
cells. Gemtuzumab ozogamicin (Mylotarg®) is a humanized antiCD33 monoclonal antibody …

Evidence regarding the efficacy of gemtuzumab ozogamicin (GO) addition to standard
induction chemotherapy in newly diagnosed acute myeloid leukaemia (AML) is conflicting …

Gemtuzumab ozogamicin was withdrawn from the market after being evaluated in
combination with chemotherapy in the frontline treatment of patients aged 18 to 60 years …

Gemtuzumab ozogamicin (GO) remained available to US clinicians through an open-label
expanded-access protocol (NCT02312037) until GO was reapproved. Patients were aged≥ …

The treatment of acute myeloid leukaemia has remained largely unchanged for the last 30
years since the advent of combination chemotherapy with cytarabine arabinoside and …